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The role of co-receptor molecules in the generation of inducible regulatory T cells (iTregs) remains incom-
pletely defined. In this issue of Immunity, Henderson et al. (2015) show that CD5 regulates iTreg cell induction
by rendering emerging iTreg cells refractory to signals mediated by effector-differentiating cytokines.CD5, a glycoprotein scavenger receptor
family transmembrane protein, is ex-
pressed on all T cells and a subset of
‘‘innate-like’’ (B-1a) B cells. Although both
activatingand inhibitory signalingactivities
have been ascribed to CD5, the effects of
germline CD5 deletion on T cell antigen re-
ceptor (TCR) signaling have unequivocally
revealed a primarily inhibitory function
for CD5 (Tarakhovsky et al., 1995). During
T cell maturation in the thymus, CD5
expression is developmentally regulated
and is induced by TCR engagement. Inter-
estingly,CD5 surface expression quantita-
tively correlates with TCR signal intensity,
and with the affinity of the TCR for posi-
tively selecting self-ligands (Azzam et al.,
2001). These results suggest that devel-
oping T cells ‘‘tune’’ their TCR signaling
response by titrating the expression of
an inhibitory molecule (CD5) to escape
negative selection thereby maximizing
the repertoire of TCRs that successfully
navigate the selection process.
In naive peripheral T cells, CD5 surface
expression is regulated by TCR contacts
with self-peptide-major histocompati-
bility complex molecules (pMHC) and is
induced by TCR signaling. Several studies
have shown that CD5hi T cells (both CD4+
and CD8+) proliferate more than CD5lo
T cells in response to contacts with self-
pMHC, indicating that CD5hi T cells ex-
press TCRs that bind with higher affinity
and/or avidity to self-pMHC (Kieper
et al., 2004; Smith et al., 2001). Recently,
it has been shown that CD5hi T cells also
respond better to agonist ligands than
CD5lo T cells, indicating that higher self-
reactivity might be predictive of stronger
binding to foreign antigens (Mandl et al.,
2013).
High surface expression of CD5 has
been one of the first phenotypic markersused to identify CD4+ suppressor regula-
tory T cells (Tregs) (Josefowicz et al.,
2012). In fact, the initial demonstration
that self-tolerance could be broken by
depletion of a specific T cell subset tested
the in vivo suppressive activity of T cells
separated on the basis of CD5 surface
expression (Sakaguchi et al., 1985). Trans-
fer of CD5lo T cells into nude (nu/nu) mice
caused autoimmune disease, whereas
transfer of CD5hi T cells or a mixture of
CD5lo and CD5hi cells did not. Whether
CD5 is simply a marker of the high TCR-
pMHCreactivity inTregcells or alsopartic-
ipates in Treg cell development, function,
or maintenance, perhaps by influencing
the TCR signaling response, is unclear.
CD5 is not required for nTreg or iTreg cell
development; however, nTreg numbers
are increased in Cd5/ mice and appear
to be more resistant to apoptosis and
more suppressive than their Cd5+/+ coun-
terparts (Soldevila et al., 2011).
In a prior study, Hawiger et al. provided
compelling evidence for a tolerogenic
function for CD5 in an experimental model
where tolerance is induced by targeted
delivery of an encephalitogenic oligo-
dendrocyte protein (MOG) to antigen-
presenting dendritic cells (DCs) in the
absence of adjuvant (Hawiger et al.,
2004). Using this model system, the au-
thors demonstrated that T cell tolerance
(as assessed by resistance to MOG-
induced experimental acute encephalo-
myelitis, EAE) was accompanied by
sustained elevation of CD5 surface
expression. They also found that this type
of T cell tolerance was CD5 dependent as
it was reversed by injection of anti-CD5
and was not observed in Cd5/mice.
Although the study by Hawiger et al.
identified a critical function for CD5 in the
induction ofDC-mediatedperipheral toler-Immunity 4ance, the role of CD5 in the generation
or suppressive function of iTreg cells in
response to tolerizing stimuli was not
directly examined. In the current report,
Henderson et al. addressed this question
using the same (MOG-DC-mediated
anergy) experimental system. In their initial
experiments, they found that the efficiency
of iTreg cell in vitro induction (as assessed
by Foxp3 expression) from polyclonal
Cd5/ CD4+ T cell precursors was
reduced compared to Cd5+/+ precursors.
Similarly, iTreg cell induction from sorted
polyclonal CD5hi T cells wasmore efficient
than from CD5lo T cells, and this effect
could not be attributed to differences in
cell survival or naive and/or memory-
phenotype precursor frequencies. How-
ever, when purified naive CD4+ T cell
precursorswereused,nosignificantdiffer-
ence in iTreg cell generationwas observed
betweenCd5/, CD5lo, andCD5hi T cells,
indicating that therewas no intrinsic differ-
ence in the potential of these T cells to
convert to iTreg cells. Based on these find-
ings, the authors speculated that CD5
modulates effects on Treg cell induction
caused by ‘‘bystander’’ effector T cells.
To test this hypothesis, they assessed
Treg cell induction of naive T cells co-
cultured with congenic CD44hi effector
T cells and found that Treg cell induction
from Cd5/ or CD5lo precursors was
reduced compared to CD5hi precursors.
Additional experiments demonstrated
that this difference was cell autonomous
and, importantly,wasalsoobserved invivo
in response to MOG-DC-mediated Treg
cell induction.
To identify the factor(s) responsible for
CD5-mediated regulation of Treg cell in-
duction, they focused on soluble effector
cytokines (interleukin-4 [IL-4], IL-6, and
interferon-g [IFN-g]), which are known to2, March 17, 2015 ª2015 Elsevier Inc. 395
Figure 1. CD5 Promotes Treg Cell Development by Inhibiting Effector-Differentiating
Cytokine Signaling
Cytokine receptor-mediated activation of mTOR is strongly inhibited in naive CD5hi T cells (left panel) but
only weakly inhibited in CD5lo T cells (right panel). mTOR activation influences the generation of iTreg cells
presumably by regulating Foxp3 induction (see Henderson et al. for details).
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Previewspromote effector T cell development and
inhibit Treg cell induction. Indeed, when
supernatants from effector T cell cultures
or purified cytokines (especially IL-6)
were added to naive Treg cell induction
assays, Treg cell generation from Cd5/
or CD5lo naive progenitors was markedly
reduced, whereas Treg cell generation
from CD5hi progenitors was less effected
even though cytokine receptor surface
expression was similar on each cell type.
In addition, upregulation of CD5 by pre-
treatment of CD5lo cells with anti-
TCR+CD28 monoclonal antibodies made
these cells less sensitive to the inhibitory
effect of IL-6 on Treg cell induction. The
authors next investigated the molecular
mechanism for CD5-mediated inhibition
of Treg cell induction. A screen of pharma-
cological inhibitors revealed that inhibition
of phosphatidyl inositol 3-OHkinase (PI3K)
or mechanistic target of rapamycin (mTor)
improved Treg cell induction by Cd5/
T cells, suggesting that CD5 inhibits cyto-
kine activation of the PI3K-Akt-mTOR
pathway (Figure 1). Although the authors
did not identify the specific intracellular
target(s) of CD5 mediated-inhibition, they
demonstrated that the requirement for
CD5 for efficient iTreg cell induction can
be bypassed by deletion ofmTor.396 Immunity 42, March 17, 2015 ª2015 ElseWhat the study by Henderson et al.
does not resolve is how CD5 actually
inhibits the PI3K-Akt-mTOR signaling
pathway in T cells or why inhibition of
mTOR favors conversion to Treg cells.
The CD5 cytoplasmic tail has been re-
ported to bind to and recruit several
putative negative regulators such as the
ubiquitin ligase c-Cbl and the protein tyro-
sine phosphatase SHP-1, and TCR stimu-
lation of Cd5/ thymocytes results in the
enhanced phosphorylation of the Rho
family guanine nucleotide exchange fac-
tor Vav and increased calcium mobiliza-
tion (Soldevila et al., 2011; Tarakhovsky
et al., 1995). However, it is unknown
whether increasing the amount of CD5
surface expression attenuates these
signaling responses. CD5 also recruits
PI3K but inhibition of PI3K or downstream
pathways by CD5 has not been demon-
strated previously (Soldevila et al., 2011)
and activation of Akt is only modestly
affected by differences in CD5 expression
in the study byHenderson et al. Moreover,
the suggestion that the mTOR pathway
is inhibitory in Treg cells is likely an over-
simplification in view of recent results
demonstrating a critical function for
mTOR for Treg cell suppressive activity
(Zeng et al., 2013).vier Inc.The findings of Henderson et al. also
raise several interesting questions for
further investigation. IL-2 receptor
signaling activates mTOR and is required
for iTreg cell development; thus it is of in-
terest to know whether CD5 also affects
this pathway. Also, CD5 has been impli-
cated in regulating T cell survival but it
is unclear whether CD5 expression influ-
ences iTreg cell survival. Finally, because
no definitive ligand has been identified for
CD5, and the PI3K-Akt-mTOR pathway is
downstream of both the TCR and cyto-
kine receptors, it is possible that CD5
inhibits signaling directly by associating
with cytokine receptors or indirectly
through its association with the TCR.
In summary, the report by Henderson
et al. sheds new light on the regulatory
function of CD5 in activated T cells and
helps explain why high-affinity TCR-
ligand interactions promote Treg cell
development. Their results also extend
the influence of CD5 to the cytokine
signaling pathway and demonstrate an
important role for this mysterious mole-
cule in chaperoning naive T cells on their
perilous journey to become iTreg cells.REFERENCES
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